Business
ViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products
ViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products\n\nViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products\n\n\nViaDerma's technology will be used in a New CBD Topical Serum in a Topical Cream, a Topical Spray and a Topical Balm, the Company will start Producing the New Products for Distribution in 400 Retail Stores in Canada for its CBD or Cannabinoids Product Line\n\nLOS ANGELES, CA--(Marketwired - January 23, 2018) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Company is working with a medical insurance consultant to get VitaStemtm , its FDA registered topical antibiotic ointment, approved for reimbursement by Health Insurance Companies. The medical insurance consultant successfully generated $70M annually for their previous product, an OTC pre-natal vitamin approved for reimbursement by insurance companies. It's marketing, sales and distribution partner, Biogenx, Inc. has been selling the product, under the name of VitaStemtm, which now retails for $79 and can be purchased online at www.Biogenx.net. ViaDerma has streamlined the manufacturing process and expects to begin its third production run of the product. The Company also expects to increase production each month as interest in the product continues to grow.The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.The Pate...